MarketPulse

Apellis Pharmaceuticals

2 articles
BenzingaBenzinga··Vandana Singh

Biogen Rallies on Pipeline Progress Despite Leqembi Review Delay

Biogen shares rise 1.06% to $193.40 despite FDA extending Leqembi review to August 2026, offset by $5.6B Apellis acquisition and Spinraza approval momentum.
APLSBIIBbiotechApellis Pharmaceuticals
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Apellis to Highlight Complement Science Portfolio at TD Cowen Healthcare Forum

Apellis will discuss its complement-targeted drug portfolio at TD Cowen Healthcare Forum in March 2026, highlighting its approved therapies for eye and kidney diseases.
APLSbiopharmaceuticalApellis Pharmaceuticals